Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
In the post-pandemic COVID-19 period, human activities have returned to normal and
COVID-19 cases are usually mild. However, patients with multiple myeloma (MM) present an …
COVID-19 cases are usually mild. However, patients with multiple myeloma (MM) present an …
[HTML][HTML] Immunogenicity of SARS-CoV-2 vaccines in patients with cancer
H Kakkassery, E Carpenter, PEM Patten… - Trends in Molecular …, 2022 - cell.com
Transmission of the SARS-CoV-2 virus and its corresponding disease (COVID-19) has been
shown to impose a higher burden on cancer patients than on the general population …
shown to impose a higher burden on cancer patients than on the general population …
Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma
A Keppler-Hafkemeyer, C Greil, PR Wratil… - Nature Cancer, 2023 - nature.com
Individuals with hematologic malignancies are at increased risk for severe coronavirus
disease 2019 (COVID-19), yet profound analyses of COVID-19 vaccine-induced immunity …
disease 2019 (COVID-19), yet profound analyses of COVID-19 vaccine-induced immunity …
[HTML][HTML] Safety and immunogenicity after a three-dose SARS-CoV-2 vaccine schedule in allogeneic stem cell transplant recipients
M Kimura, VH Ferreira, S Kothari, I Pasic… - … and cellular therapy, 2022 - Elsevier
In allogeneic stem cell transplant (Allo-SCT) recipients, the cell-mediated and humoral
immunogenicity of the 3-dose SARS-CoV-2 vaccination schedule has not been investigated …
immunogenicity of the 3-dose SARS-CoV-2 vaccination schedule has not been investigated …
Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an …
N Uaprasert, P Pitakkitnukun… - Blood Cancer …, 2022 - nature.com
Patients with hematologic malignancies (HM) have demonstrated impaired immune
responses following SARS-CoV-2 vaccination. Factors associated with poor immunogenicity …
responses following SARS-CoV-2 vaccination. Factors associated with poor immunogenicity …
Enhanced but variant-dependent serological and cellular immune responses to third-dose BNT162b2 vaccination in patients with multiple myeloma
JC Enssle, J Campe, S Büchel, A Moter, F See… - Cancer Cell, 2022 - cell.com
During the SARS-CoV-2 pandemic, patients with multiple myeloma (MM) are at increased
risk of developing severe COVID-19 and succumbing to the disease (Chari et al., 2020) …
risk of developing severe COVID-19 and succumbing to the disease (Chari et al., 2020) …
Cytokine-responsive T-and NK-cells portray SARS-CoV-2 vaccine-responders and infection in multiple myeloma patients
JC Enssle, J Campe, A Moter, I Voit, A Gessner, W Yu… - Leukemia, 2024 - nature.com
Patients with multiple myeloma (MM) routinely receive mRNA-based vaccines to reduce
COVID-19-related mortality. However, whether disease-and therapy-related alterations in …
COVID-19-related mortality. However, whether disease-and therapy-related alterations in …
Immunogenicity of SARS-CoV-2 vaccines in patients with multiple myeloma: a systematic review and meta-analysis
N Chuleerarux, K Manothummetha, C Moonla… - Blood …, 2022 - ashpublications.org
Patients with multiple myeloma (MM) have a diminished immune response to coronavirus
disease 2019 (COVID-19) vaccines. Risk factors for an impaired immune response are yet to …
disease 2019 (COVID-19) vaccines. Risk factors for an impaired immune response are yet to …
Accumulation of mutations in antibody and CD8 T cell epitopes in a B cell depleted lymphoma patient with chronic SARS-CoV-2 infection
E Khatamzas, MH Antwerpen, A Rehn, A Graf… - Nature …, 2022 - nature.com
Antibodies against the spike protein of severe acute respiratory syndrome coronavirus-2
(SARS-CoV-2) can drive adaptive evolution in immunocompromised patients with chronic …
(SARS-CoV-2) can drive adaptive evolution in immunocompromised patients with chronic …
Low spike antibody levels and impaired BA. 4/5 neutralization in patients with multiple myeloma or Waldenstrom's macroglobulinemia after BNT162b2 booster …
M Rosati, E Terpos, J Bear, R Burns, S Devasundaram… - Cancers, 2022 - mdpi.com
Simple Summary Upon BNT162b2 mRNA vaccinations, multiple myeloma (MM) and
Waldenstrom's macroglobulinemia (WM) patient cohorts on active therapy affecting B cell …
Waldenstrom's macroglobulinemia (WM) patient cohorts on active therapy affecting B cell …